GI Innovation Appoints CEO Byunggun Lee

Byeonggeon Lee, CEO and Chairman of GI Innovation

[Asia Economy Reporter Chunhee Lee] New drug development company GI Innovation has appointed Byeonggeon Lee (65) as the new CEO and Chairman.

CEO Lee earned his Ph.D. in Chemical Engineering from Rice University in the United States after graduating from Seoul National University College of Engineering and its graduate school. He has served as CEO of GC Green Cross, CEO of Green Cross Holdings, CEO of Chong Kun Dang Holdings, and CEO of SCM Life Sciences, and most recently served as Chairman of the Korea Support Committee of the International Vaccine Institute (IVI). In addition, CEO Lee has held positions such as Chairman of the Korea Bio Association, Chairman of the Advanced Regenerative Medicine Industry Council, and Director of the American Regenerative Medicine Council, establishing a global network and is recognized as a practical strategist in the pharmaceutical and bio industry.

Accordingly, GI Innovation plans to reorganize into a co-CEO system with Byeonggeon Lee and Junho Hong, pursuing company growth and increasing value through an initial public offering (IPO) and other means.

The new CEO said, “Since there are important issues such as IPO, clinical trials, and business development ahead, I will do my best to create a foundation for growth into a global company based on the know-how I have accumulated so far.” CEO Junho Hong said, “With the appointment of CEO Byeonggeon Lee, we expect significant growth for GI Innovation in many areas, and as co-CEOs, we will contribute greatly to the company’s solid growth.”

Meanwhile, GI Innovation is preparing to file for preliminary review for listing, aiming to be listed on KOSDAQ this year. It is currently conducting Phase 1 and 2 clinical trials of the immuno-oncology drug GI-101 (in Korea and the United States) and Phase 1 clinical trial of the allergy treatment GI-301 (in Korea).

This content was produced with the assistance of AI translation services.